Human epidermal growth factor receptor 2-positive breast cancer: which cytotoxic agent best complements trastuzumab’s efficacy in vitro?

INTRODUCTION: Despite trastuzumab having enhanced selectivity for human epidermal growth factor receptor 2 (HER-2) overexpressing breast cancer cells, treatment is hampered by interindividual variation and tumors with high mitogenic potential. The lack of significant clinical benefit in certain pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Hurrell, Tracey, Outhoff, Kim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3693918/
https://www.ncbi.nlm.nih.gov/pubmed/23814468
http://dx.doi.org/10.2147/OTT.S46883

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3693918/
https://www.ncbi.nlm.nih.gov/pubmed/23814468
http://dx.doi.org/10.2147/OTT.S46883

Ejemplares similares